Cantor Fitzgerald analyst Mara Goldstein maintained a Buy rating on Progenics (NASDAQ: PGNX) yesterday and set a price target of $15. The company’s shares closed on Friday at $7.23.
Goldstein said:
“. We maintain an Overweight rating and 12-month PT of $15 on the shares of PGNX. Although we like the rare disease opportunity for AZEDRA (PDUFA 7/30), we also like the PSMA-targeted pipeline for prostate cancer. Moreover, what we have come to appreciate in the PGNX story is the optionality of the pipeline, which extends to the potential for out-licensing, financing and clinical development.”
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.1% and a 39.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Karyopharm Therapeutics.
Progenics has an analyst consensus of Moderate Buy, with a price target consensus of $14.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.63 and a one-year low of $4.60. Currently, Progenics has an average volume of 1.27M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipelines are therapeutic agents, imaging agents for prostate cancer, and imaging analysis tools. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
